566 related articles for article (PubMed ID: 17454195)
21. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease.
Bossi G; Cerveri I; Volpini E; Corsico A; Baio A; Corbella F; Klersy C; Arico M
Ann Oncol; 1997; 8 Suppl 1():19-24. PubMed ID: 9187424
[TBL] [Abstract][Full Text] [Related]
22. Treatment of childhood Hodgkin's disease with chemotherapy alone. Experiences from the Royal Children's Hospital, Melbourne.
Ekert H
Cancer Treat Res; 1989; 41():241-6. PubMed ID: 2484293
[No Abstract] [Full Text] [Related]
23. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3.
Fanchin R; Schonäuer LM; Righini C; Guibourdenche J; Frydman R; Taieb J
Hum Reprod; 2003 Feb; 18(2):323-7. PubMed ID: 12571168
[TBL] [Abstract][Full Text] [Related]
24. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
[TBL] [Abstract][Full Text] [Related]
25. Avascular necrosis of the femoral head after treatment of Hodgkin's disease.
Tombolini V; Capua A; Pompili E
Acta Oncol; 1992; 31(1):64-5. PubMed ID: 1375043
[No Abstract] [Full Text] [Related]
26. Treatment of childhood Hodgkin's disease without radiotherapy.
van den Berg H; Zsiros J; Behrendt H
Ann Oncol; 1997; 8 Suppl 1():15-7. PubMed ID: 9187423
[TBL] [Abstract][Full Text] [Related]
27. [Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study].
Hassel JU; Brämswig JH; Schlegel W; Schellong G
Klin Padiatr; 1991; 203(4):268-72. PubMed ID: 1942933
[TBL] [Abstract][Full Text] [Related]
28. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease.
van den Berg H; Furstner F; van den Bos C; Behrendt H
Pediatr Blood Cancer; 2004 Mar; 42(3):210-5. PubMed ID: 14752856
[TBL] [Abstract][Full Text] [Related]
29. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome.
Eldar-Geva T; Ben-Chetrit A; Spitz IM; Rabinowitz R; Markowitz E; Mimoni T; Gal M; Zylber-Haran E; Margalioth EJ
Hum Reprod; 2005 Nov; 20(11):3178-83. PubMed ID: 16113044
[TBL] [Abstract][Full Text] [Related]
30. Decreased serum inhibin B/FSH ratio as a marker of Sertoli cell function in male survivors after chemotherapy in childhood and adolescence.
Bordallo MA; Guimarães MM; Pessoa CH; Carriço MK; Dimetz T; Gazolla HM; Dobbin J; Castilho IA
J Pediatr Endocrinol Metab; 2004 Jun; 17(6):879-87. PubMed ID: 15270406
[TBL] [Abstract][Full Text] [Related]
31. Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
Carde P; Cavalli F; Diehl V; Franklin J
Hematol J; 2000; 1(4):282-90. PubMed ID: 11920203
[No Abstract] [Full Text] [Related]
32. Chemotherapy in the treatment of Hodgkin's disease.
Canellos GP; Come SE; Skarin AT
Semin Hematol; 1983 Jan; 20(1):1-24. PubMed ID: 6189191
[No Abstract] [Full Text] [Related]
33. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa P; Bonadonna G
Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
[No Abstract] [Full Text] [Related]
34. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
35. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
36. Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.
Chatterjee R; Mills W; Katz M; McGarrigle HH; Goldstone AH
Leuk Lymphoma; 1993 Jul; 10(4-5):383-6. PubMed ID: 7693105
[TBL] [Abstract][Full Text] [Related]
37. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
Anderson RA; Remedios R; Kirkwood AA; Patrick P; Stevens L; Clifton-Hadley L; Roberts T; Hatton C; Kalakonda N; Milligan DW; McKay P; Rowntree C; Scott FM; Johnson PWM
Lancet Oncol; 2018 Oct; 19(10):1328-1337. PubMed ID: 30220622
[TBL] [Abstract][Full Text] [Related]
38. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.
Viviani S; Santoro A; Ragni G; Bonfante V; Bestetti O; Bonadonna G
Eur J Cancer Clin Oncol; 1985 May; 21(5):601-5. PubMed ID: 2408897
[TBL] [Abstract][Full Text] [Related]
39. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
40. Gonadal function following ABVD therapy for Hodgkin's disease.
Kulkarni SS; Sastry PS; Saikia TK; Parikh PM; Gopal R; Advani SH
Am J Clin Oncol; 1997 Aug; 20(4):354-7. PubMed ID: 9256888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
